查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1370932

植入前基因检测市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按程序、产品、技术、按应用、最终用途行业、地区、竞争细分

Preimplantation Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Procedure By Product, By Technology, By Application, By End-Use Industry, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 189 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022年，全球植入前基因检测（PGT）市场估值达到5.5728亿美元，预计在预测期内将大幅成长，预计复合年增长率（CAGR）为8.22%，预计将达到8.9047亿美元至2028年。

介绍：

植入前基因检测是辅助生殖技术 (ART) 领域内使用的医疗程序，用于在胚胎植入子宫之前筛选胚胎是否有遗传异常。此程序主要用于体外受精 (IVF) 治疗期间，以提高成功怀孕的机会，同时最大限度地降低将某些遗传性疾病遗传给孩子的风险。植入前基因检测有两种主要类型：

市场概况
预测期 2024-2028
2022 年市场规模 5.5728亿美元
2028 年市场规模 8.9047亿美元
2023-2028 年复合年增长率 8.22%
成长最快的细分市场 植入前遗传学诊断PGD部分
最大的市场 欧洲

1. 植入前非整倍体基因检测 (PGT-A)：此检测类型旨在筛选胚胎的染色体数量异常，特别是非整倍体。当胚胎具有异常数量的染色体时，就会发生非整倍性，可能导致流产或唐氏症等出生缺陷。 PGT-A 有助于识别具有正确染色体数量的胚胎，增加成功怀孕的可能性。

2. 单基因疾病植入前基因检测 (PGT-M)：PGT-M 用于检测已知存在于家族病史中的特定基因突变或疾病。当父母一方或双方携带已知的基因突变，可能导致其后代出现严重的健康状况（例如囊性纤维化或亨廷顿舞蹈症）时，就会使用该药物。 PGT-M 允许选择不携带基因突变的胚胎。

主要市场驱动因素：

1. 遗传性疾病发生率上升：

遗传性疾病发生率的增加是全球植入前基因检测（PGT）市场成长的重要动力。有遗传性疾病家族史或携带特定基因突变的夫妻越来越多地转向PGT，以降低将这些疾病遗传给孩子的风险。 PGT 为他们提供了一种在植入前识别未受影响的胚胎的方法，从而增加了拥有健康后代的机会。 PGT 在早期发育阶段对胚胎进行全面的遗传筛检，检测多种遗传异常，包括单基因疾病和染色体非整倍体。人们对遗传性疾病的认识不断提高，加上先进医疗技术的出现，使得更多的个人和夫妻主动寻求解决方案来减轻这些风险。

2. 基因筛检技术的进步：

基因筛检技术的进步极大地促进了全球植入前基因检测（PGT）市场的成长。这些技术创新提高了 PGT 程序的准确性、效率和可及性，使其对更广泛的个人和夫妇更具吸引力和可行性。先进的基因筛检技术在检测胚胎基因异常和突变方面提供了更高的准确性和可靠性，减少了假阳性和假阴性结果。更新的技术可以对胚胎进行全面的遗传分析，从而可以同时筛检多种遗传性疾病和染色体异常。这些创新也促进了用于胚胎评估的非侵入性或微创技术的发展，使得该过程压力更小并且可能更安全。自动化和高通量筛选技术简化了 PGT 流程，使诊所能够有效处理大量样本。

3. IVF（体外受精）需求不断成长：

对 IVF 手术的需求不断增长，大大推动了全球植入前基因检测 (PGT) 市场的成长。 IVF 和 PGT 通常会结合使用，以提高生育治疗的成功率并确保更健康的怀孕。 PGT 通常与 IVF 一起使用，以在植入前评估胚胎的遗传健康状况。随着 IVF 需求的增加，越来越多的个人和夫妻可以选择将 IVF 与 PGT 相结合，从而提高 PGT 服务的采用率。 IVF 与 PGT 的结合使医疗保健提供者能够选择遗传异常风险较低的胚胎进行植入，从而增加成功怀孕和活产的机会。

主要市场挑战：

1. 伦理和道德问题：

使用 PGT 来选择特定特征（例如眼睛颜色或智力）会引发伦理担忧，即对没有这些特征的个体可能会歧视。它可能导致基于基因组成的社会分裂。此外，PGT 用于筛检遗传疾病可能会引发有关堕胎的道德问题，因为有些人认为堕胎在道德上是错误的，而另一些人则认为在严重遗传疾病的情况下堕胎是合理的。

2. 不准确和误报/误报：

PGT 的不准确可能会导致选择患有遗传疾病的胚胎或丢弃健康的胚胎，从而影响成功怀孕的机会。假阳性和假阴性可能会对接受 PGT 的患者产生严重后果，这凸显了对高精度检测方法的需求。

3. 访问和意识有限：

PGT 相对较新，其可用性因地区而异。对于某些个人或夫妇来说，获得 PGT 服务的机会有限，尤其是在农村地区，可能会成为障碍。此外，许多人不了解 PGT 及其好处，这可能会影响他们对其使用做出明智决定的能力。

主要市场趋势：

1. 越来越多的生育诊所提供 PGT 服务：

全球植入前基因检测市场见证了越来越多的生育诊所提供 PGT 服务。这一趋势使得更多人群更容易接受 PGT 程序，使个人和夫妇能够进行基因检测并就计划生育做出明智的决定。它还促进了生育诊所之间的竞争，有可能提高服务品质、技术产品和定价。

细分洞见：

程式见解：

2022年，植入前基因检测市场主要由植入前基因诊断（PGD）主导，而这一趋势预计将持续下去。 PGD​​ 用于在植入前识别胚胎中的特定遗传缺陷或染色体异常。它通常由携带遗传性疾病并希望防止这些疾病遗传给后代的夫妇使用。

产品见解：

2022年，植入前基因检测市场主要由试药和耗材领域主导，而这种主导地位预计将持续下去。试剂和耗材是进行 PGT 程序的重要组成部分，包括准确有效测试所需的各种产品。

技术见解：

2022年，植入前基因检测市场主要由聚合酶炼式反应（PCR）领域主导，而这一趋势预计将持续下去。 PCR 因其在扩增特定 DNA 序列方面的高精度和灵敏度而受到广泛认可，非常适合 PGT 中的精确遗传分析。

应用见解：

2022年，植入前基因检测市场主要以非整倍体筛检为主，预计将持续成长。非整倍体筛检可帮助生育诊所选择染色体含量正确的胚胎，增加成功植入的机会并降低流产风险。

最终用途产业见解：

2022年，植入前基因检测市场主要由医院领域主导，预计这一趋势将持续下去。医院吸引了大量寻求生育治疗的患者，许多医院提供全面的生殖服务，包括 PGT。医院进行的先进技术和研究有助于提高检测率。

区域见解：

欧洲地区已成为全球植入前基因检测市场的领导者。欧洲发达的医疗保健系统、先进的医疗设施以及辅助生殖技术和基因检测的监管框架有助于该地区在 PGT 采用方面的突出地位。由于延迟生育和对遗传性疾病认识的提高等因素的推动，该地区对生育治疗的需求也很大。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球植入前基因检测市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依程序（植入前遗传诊断（PGD）、植入前基因筛检（PGS））
    • 按产品（试剂及耗材、仪器、软体）
    • 依技术（次世代定序、聚合酶炼式反应、萤光原位杂交等）
    • 按应用（染色体异常、X连锁疾病、胚胎检测、HLA分型、其他）
    • 依最终用途产业（生育中心、医院、诊断中心、研究中心和学术实验室）
    • 按公司划分 (2022)
    • 按地区
  • 市场地图

第 6 章：北美植入前基因检测市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按程式
    • 按产品分类
    • 按应用
    • 按最终用途行业
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 7 章：欧洲植入前基因检测市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按程式
    • 按产品分类
    • 按应用
    • 按最终用途行业
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 8 章：亚太地区植入前基因检测市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按程式
    • 按产品分类
    • 按应用
    • 按最终用途行业
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第 9 章：南美洲植入前基因检测市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按程式
    • 按产品分类
    • 按应用
    • 按最终用途行业
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲植入前基因检测市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按程式
    • 按产品分类
    • 按应用
    • 按最终用途行业
    • 按国家/地区
  • MEA：国家分析
    • 南非植入前基因检测
    • 沙乌地阿拉伯植入前基因检测
    • 阿联酋植入前基因检测

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 13 章：大环境分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • 商业概览
  • 公司概况
  • 产品与服务
  • 财务（上市公司）
  • 最近的发展
  • SWOT分析
    • California Pacific Medical Center (CPMC)
    • CombiMatrix
    • CooperSurgical, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Genea Limited
    • Genesis Genetics
    • Good Start Genetics, Inc.
    • IGENOMIX
    • Illumina, Inc.
    • Invitae Corporation
    • Laboratory Corporation of America Holdings

第 16 章：策略建议

简介目录
Product Code: 13099

The Global Preimplantation Genetic Testing (PGT) Market reached a valuation of USD 557.28 Million in 2022 and is expected to experience substantial growth in the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 8.22% and expected to reach USD 890.47 Million through 2028.

Introduction:

Preimplantation Genetic Testing is a medical procedure utilized within the realm of assisted reproductive technology (ART) to screen embryos for genetic abnormalities before their implantation into the uterus. This procedure is primarily employed during in vitro fertilization (IVF) treatments to enhance the chances of a successful pregnancy while minimizing the risk of passing certain genetic disorders to the child. There are two primary types of preimplantation genetic testing:

Market Overview
Forecast Period2024-2028
Market Size 2022USD 557.28 Million
Market Size 2028USD 890.47 Million
CAGR 2023-20288.22%
Fastest Growing SegmentPre-implantation genetic diagnosis PGD segment
Largest MarketEurope

1. Preimplantation Genetic Testing for Aneuploidy (PGT-A): This testing type is designed to screen embryos for numerical chromosomal abnormalities, particularly aneuploidies. Aneuploidy occurs when an embryo has an abnormal number of chromosomes, potentially leading to miscarriages or birth defects like Down syndrome. PGT-A helps identify embryos with the correct number of chromosomes, increasing the likelihood of a successful pregnancy.

2. Preimplantation Genetic Testing for Monogenic Disorders (PGT-M): PGT-M is employed to detect specific genetic mutations or disorders known to be present in a family's medical history. It is used when one or both parents carry a known genetic mutation that could lead to severe health conditions in their offspring, such as cystic fibrosis or Huntington's disease. PGT-M allows for the selection of embryos that do not carry the genetic mutation.

Key Market Drivers:

1. Rising Incidence of Genetic Disorders:

The increasing occurrence of genetic disorders is a significant driver for the growth of the global Preimplantation Genetic Testing (PGT) market. Couples with a family history of genetic disorders or those carrying specific genetic mutations are increasingly turning to PGT to reduce the risk of passing these disorders on to their children. PGT offers them a way to identify unaffected embryos before implantation, increasing the chances of having healthy offspring. PGT provides comprehensive genetic screening of embryos at an early developmental stage, detecting a wide range of genetic abnormalities, including single gene disorders and chromosomal aneuploidies. The rising awareness of genetic disorders and the availability of advanced medical technologies have made more individuals and couples proactive in seeking solutions to mitigate these risks.

2. Advancements in Genetic Screening Technologies:

Advancements in genetic screening technologies significantly contribute to the growth of the global Preimplantation Genetic Testing (PGT) market. These technological innovations enhance the accuracy, efficiency, and accessibility of PGT procedures, making them more attractive and feasible for a broader range of individuals and couples. Advanced genetic screening technologies offer higher accuracy and reliability in detecting genetic abnormalities and mutations in embryos, reducing false-positive and false-negative results. Newer technologies enable comprehensive genetic analysis of embryos, allowing for simultaneous screening of multiple genetic disorders and chromosomal abnormalities. These innovations also lead to the development of non-invasive or minimally invasive techniques for embryo assessment, making the procedure less stressful and potentially safer. Automation and high-throughput screening technologies streamline the PGT process, allowing clinics to handle larger volumes of samples efficiently.

3. Rising Demand for IVF (In Vitro Fertilization):

The increasing demand for IVF procedures significantly drives the growth of the global Preimplantation Genetic Testing (PGT) market. IVF and PGT are often combined to enhance the success rates of fertility treatments and ensure healthier pregnancies. PGT is commonly used alongside IVF to assess the genetic health of embryos before implantation. As the demand for IVF rises, more individuals and couples are exposed to the option of combining IVF with PGT, leading to higher adoption rates of PGT services. The combination of IVF with PGT allows healthcare providers to select embryos with a lower risk of genetic abnormalities for implantation, increasing the chances of successful pregnancies and live births.

Key Market Challenges:

1. Ethical and Moral Concerns:

The use of PGT to select for specific traits, such as eye color or intelligence, raises ethical concerns about potential discrimination against individuals without those traits. It could lead to societal divisions based on genetic makeup. Additionally, PGT's application to screen for genetic diseases may raise moral questions about abortion, as some individuals believe it is morally wrong, while others justify it in cases of serious genetic diseases.

2. Inaccuracies and False Positives/Negatives:

Inaccuracies in PGT can lead to the selection of embryos with genetic diseases or the discarding of healthy embryos, affecting the chances of a successful pregnancy. False positives and false negatives can have significant consequences for patients undergoing PGT, emphasizing the need for highly accurate testing methods.

3. Limited Access and Awareness:

PGT is relatively new, and its availability varies by region. Limited access to PGT services, especially in rural areas, can be a barrier for some individuals or couples. Additionally, many people are not aware of PGT and its benefits, which can impact their ability to make informed decisions about its use.

Key Market Trends:

1. Growing Number of Fertility Clinics Offering PGT Services:

The global Preimplantation Genetic Testing market is witnessing a growing number of fertility clinics offering PGT services. This trend makes PGT procedures more accessible to a larger population, allowing individuals and couples to access genetic testing and make informed decisions about family planning. It also fosters competition among fertility clinics, potentially leading to improvements in service quality, technology offerings, and pricing.

Segmental Insights:

Procedure Insights:

In 2022, the Preimplantation Genetic Testing market was predominantly dominated by Pre-implantation genetic diagnosis (PGD), and this trend is expected to continue. PGD is used to identify specific genetic defects or chromosomal abnormalities in embryos before implantation. It is commonly employed by couples who are carriers of genetic disorders and want to prevent the transmission of these conditions to their offspring.

Product Insights:

In 2022, the Preimplantation Genetic Testing market was primarily dominated by the reagents and consumables segment, and this dominance is expected to persist. Reagents and consumables are essential components for conducting PGT procedures, encompassing various products required for accurate and effective testing.

Technology Insights:

In 2022, the Preimplantation Genetic Testing market was mainly dominated by the polymerase chain reaction (PCR) segment, and this trend is expected to continue. PCR is widely recognized for its high accuracy and sensitivity in amplifying specific DNA sequences, making it well-suited for precise genetic analysis in PGT.

Application Insights:

In 2022, the Preimplantation Genetic Testing market was primarily dominated by aneuploidy screening, which is expected to continue its growth. Aneuploidy screening helps fertility clinics select embryos with the correct chromosomal content, increasing the chances of successful implantation and reducing the risk of miscarriages.

End-Use Industry Insights:

In 2022, the Preimplantation Genetic Testing market was mainly dominated by the hospital segment, and this trend is expected to continue. Hospitals attract a high volume of patients seeking fertility treatments, and many offer comprehensive reproductive services, including PGT. Advanced technology and research conducted in hospitals contribute to higher testing rates.

Regional Insights:

The Europe region has established itself as the leader in the global Preimplantation Genetic Testing Market. Europe's well-developed healthcare systems, advanced medical facilities, and regulatory frameworks governing assisted reproductive technologies and genetic testing contribute to the region's prominence in PGT adoption. The region also exhibits a substantial demand for fertility treatments, driven by factors such as delayed parenthood and increased awareness of genetic disorders.

Key Market Players

  • California Pacific Medical Center (CPMC)
  • CombiMatrix Corp
  • CooperSurgical, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genea Limited
  • Genesis Genetics
  • Good Start Genetics, Inc.
  • IGENOMIX
  • Illumina, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings

Report Scope:

In this report, the Global Preimplantation Genetic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Preimplantation Genetic Testing Market, By Procedure:

  • Pre-implantation genetic diagnosis (PDS)
  • Preimplantation Genetic Screening (PGS)

Preimplantation Genetic Testing Market, By Product:

  • Reagents and Consumables
  • Instruments
  • Software

Preimplantation Genetic Testing Market, By Technology:

  • Next Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescent In-Situ Hybridization (FISH)
  • Others

Preimplantation Genetic Testing Market, By Application:

  • Chromosomal Abnormalities
  • X-linked Diseases
  • Embryo Testing
  • Aneuploidy Screening
  • HLA Typing
  • Other Applications

Global Preimplantation Genetic Testing Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Preimplantation Genetic Testing Market.

Available Customizations:

  • Global Preimplantation Genetic Testing Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Preimplantation Genetic Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Procedure (Pre-implantation genetic diagnosis (PGD), preimplantation genetic screening (PGS))
    • 5.2.2. By Product (Reagents and Consumables, Instruments, Software)
    • 5.2.3. By Technology (Next Generation Sequencing, Polymerase Chain Reaction, Fluorescent In-Site Hybridization, Others)
    • 5.2.4. By Application (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, HLA Typing, Others)
    • 5.2.5. By End-Use Industry (Fertility Centres, Hospitals, Diagnostics Centres, Research Centres And Academic Labs)
    • 5.2.6. By Company (2022)
    • 5.2.7. By Region
  • 5.3. Market Map

6. North America Preimplantation Genetic Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Procedure
    • 6.2.2. By Product
    • 6.2.3. By Application
    • 6.2.4. By End-Use Industry
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Preimplantation Genetic Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Procedure
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End-Use Industry
    • 6.3.2. Mexico Preimplantation Genetic Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Procedure
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End-Use Industry
    • 6.3.3. Canada Preimplantation Genetic Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Procedure
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End-Use Industry

7. Europe Preimplantation Genetic Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Procedure
    • 7.2.2. By Product
    • 7.2.3. By Application
    • 7.2.4. By End-Use Industry
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Preimplantation Genetic Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Procedure
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End-Use Industry
    • 7.3.2. Germany Preimplantation Genetic Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Procedure
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End-Use Industry
    • 7.3.3. United Kingdom Preimplantation Genetic Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Procedure
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End-Use Industry
    • 7.3.4. Italy Preimplantation Genetic Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Procedure
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End-Use Industry
    • 7.3.5. Spain Preimplantation Genetic Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Procedure
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End-Use Industry

8. Asia-Pacific Preimplantation Genetic Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Procedure
    • 8.2.2. By Product
    • 8.2.3. By Application
    • 8.2.4. By End-Use Industry
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Preimplantation Genetic Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Procedure
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End-Use Industry
    • 8.3.2. India Preimplantation Genetic Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Procedure
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End-Use Industry
    • 8.3.3. South Korea Preimplantation Genetic Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Procedure
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End-Use Industry
    • 8.3.4. Japan Preimplantation Genetic Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Procedure
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End-Use Industry
    • 8.3.5. Australia Preimplantation Genetic Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Procedure
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End-Use Industry

9. South America Preimplantation Genetic Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Procedure
    • 9.2.2. By Product
    • 9.2.3. By Application
    • 9.2.4. By End-Use Industry
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Preimplantation Genetic Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Procedure
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End-Use Industry
    • 9.3.2. Argentina Preimplantation Genetic Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Procedure
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End-Use Industry
    • 9.3.3. Colombia Preimplantation Genetic Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Procedure
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End-Use Industry

10. Middle East and Africa Preimplantation Genetic Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Procedure
    • 10.2.2. By Product
    • 10.2.3. By Application
    • 10.2.4. By End-Use Industry
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Preimplantation Genetic Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Procedure
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End-Use Industry
    • 10.3.2. Saudi Arabia Preimplantation Genetic Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Procedure
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End-Use Industry
    • 10.3.3. UAE Preimplantation Genetic Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Procedure
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End-Use Industry

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. California Pacific Medical Center (CPMC)
    • 15.6.2. CombiMatrix
    • 15.6.3. CooperSurgical, Inc.
    • 15.6.4. F. Hoffmann-La Roche Ltd.
    • 15.6.5. Genea Limited
    • 15.6.6. Genesis Genetics
    • 15.6.7. Good Start Genetics, Inc.
    • 15.6.8. IGENOMIX
    • 15.6.9. Illumina, Inc.
    • 15.6.10. Invitae Corporation
    • 15.6.11. Laboratory Corporation of America Holdings

16. Strategic Recommendations